Navigation Links
BioMed Realty Trust Announces Exercise of Over-Allotment Option

SAN DIEGO, Oct. 6 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that on October 1, 2008 the underwriter exercised its over-allotment option in full to purchase an additional 1,125,000 shares of common stock in connection with BioMed's previously announced offering that priced on October 1, 2008. In total, the company sold 8,625,000 shares of common stock, raising net proceeds of approximately $212.4 million after deducting underwriter discounts and commissions and estimated expenses. UBS Investment Bank is acting as the sole underwriter for the offering.

The registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of BioMed's common stock, nor shall there be any sale of such common stock in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. The offering of BioMed's common stock is made only by means of a prospectus and a related prospectus supplement, copies of which may be obtained from

UBS Investment Bank

Prospectus Department

299 Park Avenue

New York, NY 10171

or by telephone toll free at 888-827-7275, extension 3884.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 69 properties, representing 112 buildings with approximately 10.4 million rentable square feet, including approximately 1.9 million square feet of development in progress. The company also owns undeveloped land parcels adjacent to existing properties that it estimates can support up to 1.4 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE BioMed Realty Trust, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
2. BioMed Realty Trust Declares Third Quarter 2007 Common Stock and Preferred Stock Dividends
3. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
4. Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test
5. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
6. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
7. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
8. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
9. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
10. Environmental Tectonics Corporations BioMedical Division Announces New Contract
11. Avery Biomedical Devices, Inc. Appoints Elefteriades to its Board of Directors
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/26/2015)... 26, 2015 --> ... in imaging technologies, announced today that it has received a ... the Horizon 2020 European Union Framework Programme for Research and ... trial in breast cancer. , --> ... --> --> The study aims to ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
(Date:10/27/2015)... -- In the present market scenario, security is one ... verticals such as banking, healthcare, defense, electronic gadgets, and ... secure & simplified access control and growing rate of ... bank accounts, misuse of users, , and so on. ... and smartphones are expected to provide potential opportunities for ...
(Date:10/26/2015)... October 26, 2015 ... adds Biometrics Market Shares, ... as well as Emerging Biometrics Technologies: ... to its collection of IT and ... . --> ...
Breaking Biology News(10 mins):